市場調查報告書
商品編碼
1378822
2023-2028 年按類型、應用(心室內不同步、心室間不同步、房室不同步)、最終用戶和地區分類的心臟再同步治療市場報告Cardiac Resynchronization Therapy Market Report by Type, Application (Intraventricular Dyssynchrony, Interventricular Dyssynchrony, Atrioventricular Dyssynchrony), End User, and Region 2023-2028 |
2022年,全球心臟再同步治療(CRT)市場規模達到54億美元。展望未來, IMARC Group預計到2028年市場規模將達到77億美元,2022-2028年複合年成長率(CAGR)為6.1%。心臟衰竭盛行率的上升、政府和監管支持的增加、有利的報銷政策以及新興經濟體醫療基礎設施的擴張是推動市場的一些主要因素。
心臟再同步治療(CRT)是一種先進的醫療程序,用於治療某些患者的心臟衰竭症狀。這種治療涉及使用一種透過手術植入胸部的專用設備,稱為 CRT 設備,類似於起搏器。該裝置的工作原理是向心室傳輸電脈衝,從而協調它們的收縮。這種同步可以提高心臟的效率,減輕經常伴隨心臟衰竭的疲勞和呼吸急促等症狀。對於患有中度至重度心臟衰竭且心臟內電紊亂證據的個體,通常會考慮 CRT 並結合最佳的藥物治療。 CRT的實施標誌著一種有針對性的心臟衰竭管理方法,旨在提高患者的生活品質和整體功能能力。
醫療保健基礎設施的快速發展,特別是在新興經濟體,在擴大 CRT 設備的覆蓋範圍方面發揮著至關重要的作用,這將刺激預測期內的市場成長。隨著各國投資現代化醫療設施、培訓醫療保健專業人員和加強醫療保健系統,獲得 CRT 等專業治療的機會變得越來越普遍。再加上醫療旅遊業的興起,患者在以具有競爭力的成本提供先進醫療技術的國家尋求治療,正在推動市場成長。此外,不斷增加的公私夥伴關係正在促進政府和私人實體之間的合作,以資助和促進 CRT。透過教育活動和專業研討會提高患者意識也促進了 CRT 的理解和接受,加快了產品的採用率。此外,製造商之間在產品開發、行銷和分銷方面的策略合作正在支持市場成長。除此之外,提供具有成本效益的 CRT 解決方案的本地製造商的出現正在促進競爭並使治療更容易獲得,從而推動心臟再同步治療市場的成長。
心臟衰竭盛行率增加
全球心臟衰竭發生率的上升是推動心臟再同步治療(CRT)市場成長的關鍵因素。隨著心臟衰竭變得越來越普遍,特別是在人口老化以及肥胖和糖尿病發病率增加的地區,對 CRT 等有效治療方法的需求正在增加。 CRT 能夠改善特定心臟衰竭患者的症狀和整體生活品質,這凸顯了其重要性。各種公共衛生措施也強調心臟衰竭的早期發現和治療,進一步推動了對 CRT 的需求。這種慢性疾病的日益普及需要不斷改進治療解決方案,使 CRT 成為當代心臟衰竭管理策略不可或缺的一部分。
科技的快速進步
CRT 領域的技術創新和進步為全球市場的成長做出了重大貢獻。主要參與者加大研發 (R&D) 力度,不斷改進 CRT 設備,提升其功效、安全性和病患相容性。多點起搏和自適應演算法等創新正在實現更個人化和高效的治療,滿足心臟衰竭患者的多樣化需求。先進技術的整合也有助於與其他醫療系統和患者監測工具的無縫協調。技術的不斷發展將 CRT 的益處擴展到更廣泛的患者群體,同時確保該療法始終處於心臟衰竭治療的前沿。
有利的政府和監管支持
政府和監管支援在塑造 CRT 市場方面發揮著至關重要的作用。透過提供明確的監管途徑,政府正在促進新的和改進的 CRT 設備更快地獲得批准。許多國家也投資於研究計劃,並與產業參與者合作,以促進該領域的創新。此外,政府支持的衛生計劃和政策的重點是減輕心臟衰竭的負擔,因此支持 CRT 等治療方法。監管機構與加強心臟衰竭護理目標的這種一致表明了一種堅定的方法,這有助於促進成長、標準化實踐和確保 CRT 在各個醫療保健系統中的可及性。
IMARC Group提供了全球心臟再同步治療 (CRT) 市場報告各細分市場的主要趨勢分析,以及 2023-2028 年全球、區域和國家層面的預測。我們的報告根據類型、應用程式和最終用戶對市場進行了分類。
CRT-去顫器
CRT心律調節器
CRT-除顫器代表最受歡迎的類型
該報告根據類型提供了詳細的市場細分和分析。這包括 CRT 除顫器和 CRT 起搏器。根據該報告,CRT-除顫器佔據了最大的細分市場。
CRT 去顫器 (CRT-D) 提供治療心臟衰竭患者的雙重功能。與標準 CRT 設備不同,CRT-D 結合了心臟再同步功能和去顫功能。這種整合方法使設備能夠同步心室,提高其效率,並檢測和糾正危及生命的心律不整。當檢測到心律不整時,CRT-D 會向心臟發出電擊,從而起到保護作用,為心臟驟停高風險患者提供額外的保護。 CRT-D 的包羅萬象的性質擴展了其適用性,為治療心臟衰竭的慢性症狀和急性、嚴重心律不整提供了全面的解決方案。此外,設備小型化、電池壽命和可編程性的改進也促進了其普及。將功能整合到一台設備中,提供多方面的護理,使 CRT-D 成為首選,從而推動了該細分市場的成長。
心室內不同步
室間 (VV) 不同步
房室 (AV) 不同步
心室內不同步主導市場
該報告根據應用程式提供了詳細的市場細分和分析。這包括心室內不同步、室間 (VV) 不同步和房室 (AV) 不同步。根據該報告,心室內不同步是最大的部分。
心室內不同步是指心室收縮不協調,導致泵血效率低下和心臟衰竭症狀惡化。這種特殊形式的不同步已在大量心臟衰竭患者中被發現,使其成為 CRT 的主要目標。 CRT 在治療心室內不同步方面的應用已被廣泛認可,可顯著改善症狀和整體心臟功能。透過 CRT 精確定位和糾正這種不同步,使心臟能夠更有效地泵血,從而提高患者的生活品質並降低住院率。研究和臨床試驗進一步支持了 CRT 在此應用中的有效性,鞏固了其作為標準治療的地位。心臟衰竭患者普遍存在心室內不同步現象,而 CRT 在解決這種情況方面已被證明是成功的,這些都推動了該細分市場的成長。
醫院
心臟中心
門診手術中心
其他
醫院佔最大市場佔有率
報告還提供了基於最終用戶的詳細市場細分和分析。這包括醫院、心臟中心、門診手術中心等。報告顯示,醫院佔據了最大的市場。
醫院通常是診斷和治療心臟衰竭的主要場所,包括 CRT 設備的植入和管理。 CRT 的複雜性需要專門的設備、熟練的醫療保健專業人員以及協調的術後護理,而醫院通常有能力提供這些資源。此外,較大的醫院通常設有專門的心臟科室,配備經過 CRT 專門培訓的專家,從而實現從初步諮詢到術後監測的全面患者護理。許多醫院也參與研究並與設備製造商合作,進一步與 CRT 的進步保持一致。對綜合護理途徑的重視,再加上醫院環境內多學科團隊的支持,確保患者獲得無縫的體驗。這種資源、專業知識和以患者為中心的護理的結合正在支持醫院部門的成長。
北美洲
美國
加拿大
亞太地區
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美在市場上表現出明顯的主導地位
該報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告稱,北美佔據最大的市場佔有率。
北美佔據了最大的市場佔有率,因為該地區擁有先進的醫療基礎設施、對醫療創新的重視以及強力的監管支持,為 CRT 的採用和發展創造了有利的環境。北美也擁有大量領先的醫療研究機構和設備製造商,推動了CRT技術的持續創新。此外,醫療保健專業人員和一般大眾對心臟衰竭及其治療方案的認知程度較高,也有助於 CRT 的接受度不斷提高。此外,導致心臟衰竭的生活方式相關疾病的盛行率相對較高,形成了龐大的患者基礎。優惠的報銷政策和保險範圍進一步方便了患者接受 CRT 治療。這些因素,加上對以患者為中心的護理的日益關注,使北美成為心臟再同步治療 (CRT) 最大的區域市場。
由於主要參與者積極參與研發 (R&D),努力創新和增強 CRT 技術,市場正在穩步成長。他們與醫療保健機構合作,專注於創建提高效率、患者相容性以及與其他醫療保健系統整合的設備。擴展到新興市場以及與當地經銷商建立策略聯盟也是其成長策略的一部分。透過收購和合作,這些產業領導者正在鞏固自己的影響力、分享專業知識並促進技術進步。投資臨床試驗來驗證新應用,並持續與監管機構合作以確保合規性,確保符合全球醫療保健需求。我們也預期市場將出現新進業者、產品組合整合以及策略合作的增加,以推動 CRT 領域內的良性競爭。
雅培實驗室
百多力股份公司
波士頓科學公司
利瓦諾瓦公司
麥迪科公司
美敦力公司
梅里特醫療系統公司
微創醫療科技有限公司
2023 年 7 月,Biotronik SE & Co. KG 宣布美國食品藥物管理局 (FDA) 批准其下一代 Amvia Edge 起搏器和心臟再同步治療 (CRT) 設備產品組合。
雅培實驗室 (Abbott Laboratories) 在心臟再同步治療 (CRT) 領域取得了最新進展,發布了其植入式起搏器和除顫器的更新版本,展示了其不斷改善患者護理的承諾。
The global cardiac resynchronization therapy (CRT) market size reached US$ 5.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.1% during 2022-2028. The rising prevalence of heart failure, increase in government and regulatory support, favorable reimbursement policies, and expansion of healthcare infrastructure in emerging economies are some of the major factors propelling the market.
Cardiac resynchronization therapy (CRT) is an advanced medical procedure used to treat heart failure symptoms in certain patients. This treatment involves the use of a specialized device that is surgically implanted in the chest, known as a CRT device, which is akin to a pacemaker. The device functions by transmitting electrical impulses to the chambers of the heart, thereby coordinating their contractions. This synchronization can enhance the heart's efficiency, alleviating symptoms such as fatigue and shortness of breath that often accompany heart failure. CRT is typically considered for individuals with moderate to severe heart failure who display evidence of electrical disarray within the heart, in conjunction with optimal medical therapy. The implementation of CRT signifies a targeted approach to heart failure management, aimed at improving the quality of life and overall functional capacity of patients.
Rapid healthcare infrastructure development, particularly in emerging economies, is playing a vital role in expanding the reach of CRT devices, which will stimulate market growth during the forecast period. As nations invest in modernizing medical facilities, training healthcare professionals, and strengthening healthcare systems, access to specialized treatments like CRT is becoming more widespread. This, coupled with a rise in medical tourism, where patients seek treatment in countries offering advanced healthcare technologies at competitive costs, is fueling the market growth. Furthermore, the increasing public-private partnerships are fostering collaborations between governments and private entities to finance and promote CRT. Enhanced patient awareness through educational campaigns and professional workshops is also facilitating the understanding and acceptance of CRT, accelerating the product adoption rate. In addition, strategic collaborations between manufacturers for product development, marketing, and distribution are supporting market growth. Besides this, the emergence of local manufacturers offering cost-effective CRT solutions is fostering competition and making therapy more accessible, thus propelling the growth of the cardiac resynchronization therapy market.
Increase in Prevalence of Heart Failure
The rising incidence of heart failure globally is a key factor driving the growth of the cardiac resynchronization therapy (CRT) market. As heart failure becomes more prevalent, particularly in aging populations and areas with increased rates of obesity and diabetes, the demand for effective treatments like CRT is escalating. The ability of CRT to improve symptoms and overall quality of life in selected patients with heart failure underscores its importance. Various public health initiatives are also emphasizing early detection and treatment of heart failure, further propelling the need for CRT. The growing prevalence of this chronic condition necessitates continuous advancement in therapeutic solutions, making CRT an integral part of contemporary heart failure management strategies.
Rapid Technological Advancements
Technological innovation and advancements in the field of CRT are contributing significantly to the growth of the global market. Increased research and development (R&D) efforts by key players are continuously refining CRT devices, enhancing their efficacy, safety, and patient compatibility. Innovations like multi-point pacing and adaptive algorithms are enabling more personalized and efficient therapies, catering to the diverse needs of heart failure patients. The integration of sophisticated technologies also facilitates seamless coordination with other medical systems and patient monitoring tools. This constant evolution in technology is extending the benefits of CRT to a wider patient demographic while ensuring that the therapy remains at the forefront of heart failure treatment.
Favorable Government and Regulatory Support
Government and regulatory support play a crucial role in shaping the CRT market. By providing clear regulatory pathways, governments are facilitating faster approvals of new and improved CRT devices. Many countries are also investing in research initiatives and collaborating with industry players to foster innovation in the field. Moreover, government-backed health programs and policies are focusing on reducing the burden of heart failure and are thus endorsing treatments like CRT. This alignment of regulatory bodies with the objective of enhancing heart failure care demonstrates a committed approach, which is instrumental in fostering growth, standardizing practices, and ensuring the accessibility of CRT across various healthcare systems.
IMARC Group provides an analysis of the key trends in each segment of the global cardiac resynchronization therapy (CRT) market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on type, application, and end user.
CRT-Defibrillator
CRT-Pacemaker
CRT-Defibrillator represents the most popular type
The report has provided a detailed breakup and analysis of the market based on the type. This includes CRT-Defibrillator and CRT-Pacemaker. According to the report, CRT-Defibrillator represented the largest segment.
The CRT-Defibrillator (CRT-D) offers dual functionality in treating heart failure patients. Unlike standard CRT devices, CRT-D combines the features of cardiac resynchronization with defibrillation capabilities. This integrated approach enables the device to synchronize the heart's chambers, improving its efficiency, as well as to detect and correct life-threatening arrhythmias. By delivering a shock to the heart when it detects irregular rhythms, the CRT-D acts as a safeguard, adding an extra layer of protection for patients at high risk of sudden cardiac arrest. The all-encompassing nature of CRT-D extends its applicability, offering a comprehensive solution for managing both the chronic symptoms of heart failure and acute, critical arrhythmias. Additionally, improvements in device miniaturization, battery life, and programmability have contributed to its popularity. This consolidation of functions into one device, providing multifaceted care, has made CRT-D a preferred option, thus fueling the segment growth.
Intraventricular Dyssynchrony
Interventricular (V-V) Dyssynchrony
Atrioventricular (A-V) Dyssynchrony
Intraventricular Dyssynchrony dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes intraventricular dyssynchrony interventricular (V-V) dyssynchrony, and atrioventricular (A-V) dyssynchrony. According to the report, intraventricular dyssynchrony represented the largest segment.
Intraventricular dyssynchrony refers to the uncoordinated contraction of the heart's ventricles, leading to inefficient pumping and worsening heart failure symptoms. This specific form of dyssynchrony has been identified in a significant number of heart failure patients, making it a primary target for CRT. The use of CRT in managing intraventricular dyssynchrony is well-established, offering marked improvements in both symptoms and overall cardiac function. The precise targeting and correction of this dyssynchrony through CRT enables the heart to pump more efficiently, enhancing the patient's quality of life and reducing hospitalization rates. Research studies and clinical trials have further supported the effectiveness of CRT in this application, solidifying its position as a standard treatment. The pervasive presence of intraventricular dyssynchrony among heart failure patients and the proven success of CRT in addressing this condition are fueling the segment growth.
Hospitals
Cardiac Centers
Ambulatory Surgery Centers
Others
Hospitals hold the largest share in the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, cardiac centers, ambulatory surgery centers, and others. According to the report, hospitals accounted for the largest market share.
Hospitals are often the primary setting for the diagnosis and treatment of heart failure, including the implantation and management of CRT devices. The complexity of CRT requires specialized equipment, skilled healthcare professionals, and coordinated post-procedure care, resources that hospitals are typically well-equipped to provide. Additionally, larger hospitals often have dedicated cardiac units with experts trained specifically in CRT, enabling comprehensive patient care from initial consultation through post-surgical monitoring. Many hospitals also engage in research and collaborate with device manufacturers, further aligning themselves with the advancements in CRT. The emphasis on integrated care pathways, coupled with the support of multi-disciplinary teams within the hospital setting, ensures that patients receive a seamless experience. This combination of resources, expertise, and patient-centric care is supporting the growth of the hospital segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region boasts a sophisticated healthcare infrastructure, emphasis on medical innovation, and robust regulatory support that have fostered a favorable environment for the adoption and advancement of CRT. North America is also home to a significant number of leading medical research institutions and device manufacturers, promoting continuous innovation in CRT technology. In addition, high awareness levels among healthcare professionals and the general population about heart failure and its treatment options contribute to the growing acceptance of CRT. Moreover, the prevalence of lifestyle-related diseases leading to heart failure is relatively high in this region, creating a substantial patient base. Favorable reimbursement policies and insurance coverage further ease the accessibility of CRT for patients. These factors, along with the increasing focus on patient-centered care, position North America as the largest regional market for cardiac resynchronization therapy (CRT).
The market is experiencing steady growth as key players are actively engaged in research and development (R&D), striving to innovate and enhance CRT technology. Collaborating with healthcare institutions, they are focused on creating devices with improved efficiency, patient compatibility, and integration with other healthcare systems. Expansion into emerging markets and strategic alliances with local distributors are also part of their growth strategies. Through acquisitions and partnerships, these industry leaders are consolidating their presence, sharing expertise, and fostering technological advancements. Investments in clinical trials to validate new applications and continued engagement with regulatory bodies for compliance ensure alignment with global healthcare needs. We also expect the market to witness new entrants, consolidation of portfolios, and a rise in strategic collaborations to drive healthy competition within the CRT domain.
Abbott Laboratories
Biotronik SE & Co. KG
Boston Scientific Corporation
LivaNova Plc
Medico S.p.A.
Medtronic Plc
Merit Medical Systems Inc.
MicroPort Scientific Corporation
In July 2023, Biotronik SE & Co. KG announced the approval of its next-generation portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy (CRT) devices by the U.S. Food and Drug Administration (FDA).
Abbott Laboratories has made recent developments in cardiac resynchronization therapy (CRT) by releasing updates to its implantable pacemakers and defibrillators, showcasing its commitment to continuously improve patient care.